Pharvaris Shares HAE Development Data at 2024 ACAAI Meeting

Pharvaris, a biopharmaceutical enterprise based in Zug, Switzerland, is making significant strides in the development of oral treatments for hereditary angioedema (HAE). The company recently revealed data from seven research posters set to be presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). These findings underscore the promising potential of their novel drug, deucrictibant.

Pharvaris is deeply saddened by the loss of Professor Marcus Maurer, who played a crucial role in the development and finalization of these research posters. According to Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris, the comprehensive data from these studies continue to affirm the potential of deucrictibant as a leading therapy, providing further validation for its ongoing clinical progress.

Deucrictibant has shown impressive results in the CHAPTER-1 Phase 2 trial, which aims to evaluate its efficacy and safety in preventing HAE attacks. Presented by Dr. H. James Wedner, the study highlights deucrictibant’s ability to reduce the median percentage of days with HAE symptoms from 14.6% to 1.7% at a dosage of 40 mg per day. The ongoing CHAPTER-1 open-label extension study, presented by Dr. John Anderson, provides additional evidence of the drug's long-term safety and efficacy. Remarkably, approximately 80% of the participants in the study achieved at least a 90% reduction in attack rates compared to the study baseline.

Supporting the confidence in the design and potential of deucrictibant, nonclinical data in the bradykinin (BK) challenge model in non-human primates (NHPs) have been pivotal. Presented by Juan Bravo, Ph.D., these studies showed that the pharmacokinetic and pharmacodynamic (PK/PD) profiles of deucrictibant in NHPs could predict similar outcomes in humans. This predictive accuracy has been confirmed through in-house modeling of nonclinical data, aligning with the results observed in Phase 2 clinical trials for both prophylactic and on-demand treatments.

The innovative drug, deucrictibant, is an oral bradykinin B2 receptor antagonist developed by Pharvaris. By targeting and inhibiting bradykinin signaling, deucrictibant aims to prevent HAE attacks and treat symptoms effectively when they occur. Pharvaris is advancing two oral formulations of deucrictibant: an extended-release tablet designed for sustained efficacy in prophylactic treatment and an immediate-release capsule for rapid action during on-demand treatment.

Pharvaris is dedicated to providing effective, well-tolerated, and convenient treatment options for individuals with HAE. With encouraging results from both Phase 2 studies for prophylactic and on-demand applications, the company is moving forward with pivotal Phase 3 trials. Pharvaris is currently enrolling participants for a Phase 3 study focused on the on-demand treatment of HAE attacks and plans to commence a similar study for the prevention of attacks by the end of 2024.

By leveraging clinically proven therapeutic targets with novel small molecules, Pharvaris aims to improve the quality of life for people with HAE through innovative and user-friendly treatments. The company's endeavors reflect a significant advancement in the management and treatment of HAE, promising new avenues for effective and accessible care.